By Fineline Cube 
AstraZeneca plc (NYSE: AZN) announced that China’s National Medical Products Administration (NMPA) has approved Tezspire® (tezepelumab)—a first-in-class thymic stromal lymphopoietin (TSLP)-targeted monoclonal antibody co-developed with Amgen (NASDAQ: AMGN)—for two new indications:
- Add-on maintenance treatment of severe asthma in adults and adolescents aged 12+ years
- Combination therapy with intranasal glucocorticoids for chronic rhinosinusitis with nasal polyps (CRSwNP) in adults inadequately controlled by systemic steroids or surgery
Approvals were based on robust results from the Phase III DIRECTION (asthma) and WAYPOINT (CRSwNP) trials, positioning Tezspire as the first biologic in China to target TSLP upstream in the inflammatory cascade.
Pivotal Trial Results
DIRECTION Study – Severe Asthma
| Endpoint | Tezepelumab vs. Placebo |
|---|---|
| Annualized Asthma Exacerbation Rate (AAER) | 74% reduction (p<0.001) |
| Patient Population | Broad severe asthma cohort (eosinophil-low and -high) |
WAYPOINT Study – CRSwNP
| Endpoint | Tezepelumab vs. Placebo |
|---|---|
| Nasal Polyp Severity | Statistically significant & clinically meaningful improvement (p<0.0001) |
| Surgery Avoidance | Near elimination of need for sinus surgery (p<0.0001) |
| Systemic Glucocorticoid Use | Significant reduction (p<0.0001) |
These data confirm Tezspire’s ability to modulate type 2 inflammation at its source, offering benefits across multiple TSLP-driven conditions.
Mechanism & Differentiation
- Target: Thymic stromal lymphopoietin (TSLP)—an epithelial cytokine acting as a master switch for allergic inflammation
- First-in-Class: Only approved biologic that blocks TSLP upstream of IL-4, IL-5, and IL-13
- Broad Applicability: Effective regardless of eosinophil levels, unlike anti-IL5/IL4R agents
- Dual Indication Synergy: Enables treatment of comorbid asthma and CRSwNP—a common clinical phenotype affecting ~30% of severe asthma patients
In China, where severe asthma affects over 6 million and CRSwNP remains undertreated, Tezspire addresses a critical therapeutic gap.
Strategic Implications
- Market Entry: First global launch of Tezspire in CRSwNP indication, ahead of U.S. and EU filings
- Commercial Advantage: Dual approval allows cross-specialty promotion to pulmonologists and ENT physicians
- Pricing Power: Potential for premium reimbursement given surgery and steroid-sparing benefits
- Partnership Leverage: Reinforces AstraZeneca–Amgen collaboration, with Amgen retaining U.S. rights and AstraZeneca leading ex-U.S. commercialization
With China representing the world’s largest respiratory disease market, this approval could drive significant long-term revenue growth.
Forward‑Looking Statements
This brief contains forward-looking statements regarding market adoption, reimbursement, and clinical impact. Actual outcomes may vary due to physician prescribing patterns, payer coverage decisions, and competitive dynamics.-Fineline Info & Tech